Mirum Pharmaceuticals

Mirum Pharmaceuticals is a biopharmaceutical company focused on rare diseases. It was founded in November 2018 in the San Francisco Bay Area. The company develops and delivers treatments for rare diseases, with a focus on conditions where the burden is profound and the need is greatest. It has three approved medicines and a broad pipeline of investigational medicines.

Mirum Pharmaceuticals was founded in November 2018 in the San Francisco Bay Area with a clear goal: to advance a promising therapy for children living with Alagille syndrome, a rare liver disease marked by significant unmet need. The company began with an investigational program that had been deprioritized by a larger organization despite compelling potential. That therapy is now LIVMARLI, approved for the treatment of cholestatic pruritus in Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC), with additional development programs underway.

• 2021.06.07

  Reported2021.06.07

  Mirum appoints Carol L. Brosgart to its board[6]Mirum任命Carol L. Brosgart为董事会成员biospace.com

  Mirum Pharmaceuticals announced the appointment of Carol L. Brosgart as an independent director to its board of directors.

Read more

1. 1Mirum Pharmaceuticals | Relentlessly Raremirumpharma.com
2. 2Our Story | Mirum Pharmaceuticalsmirumpharma.com
3. 3Leadership | Mirum Pharmaceuticalsmirumpharma.com
4. 4Contact Us | Mirum Pharmaceuticalsmirumpharma.com
5. 5Mirum Pharmaceuticalswikidata.org
6. 6Mirum任命Carol L. Brosgart为董事会成员biospace.com